Intel Overtakes Pfizer as Most Shorted Dow Stock

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or at least for their share prices to fall handily. Plus, those sellers are responsible for paying the dividends on the stocks they short.

Maybe it is little wonder that only two of the 30 Dow stocks had notable short interest between June 28 and July 15; that is, more than 50 million shares short. In fact, just seven of them had short interest of more than 30 million shares.

While the bull market is quite long in the tooth — more than 10 years old — and concern about a possible recession remains as the trade war with China drags on, the markets are still near all-time highs. Investors may wonder then what the short sellers expect from some of the biggest, most well-respected names on Wall Street.

As of the July 15 settlement date, the most recently reported period, short sellers favored Intel Corp. (NASDAQ: INTC), Pfizer Inc. (NYSE: PFE) and Microsoft Corp. (NASDAQ: MSFT) above all other Dow stocks.

> Shares short: over 61.05 million
> Change from prior period: 9.2%
> Percentage of float: 1.4

The number of shares short has now increased in three of the past five periods, and it has only been higher in one other period this year. The average daily trading volume decreased again in the latest period, and as of the middle of this month, it would take more than three days for investors to cover all their short positions.

A profit warning from Samsung weighed on semiconductor leaders during the period. The share price ended the first two weeks of July 1% or so higher, though it had been down almost 4% earlier in the month. The Nasdaq also saw a gain of more than 1% in that time as well, though it pulled back a bit afterward.

Intel was trading most recently at $52.92 a share, down handily from the multiyear high of $59.59 seen this spring. The 52-week low is $42.36 per share. Note that the latest share price is more than 12% higher than at the beginning of the year, while the Nasdaq is up more than 25% year to date and the Dow has seen a gain of almost 17%.

> Shares short: about 57.72 million
> Change from prior period: 1.3%
> Percentage of float: 1.0

Pfizer’s reign as king of the hill, which began in May, has ended, with this stock dropping to the number two spot on this list despite a marginal increase in short interest in the latest period. Note though that the latest figure is nowhere near the 156 million shares short back in January.

Pfizer released some disappointing trial data at the end of June, but like other drugmakers benefited from a court ruling on prices this month. The shares ended the short interest period less than 2% lower than where they started, though they had been up over 2% at one point. Meanwhile, the Dow gained almost 2% between the settlement dates.

Shares closed most recently at $42.89 apiece, about the same price as a week ago. Pfizer’s 52-week low of $37.56 was seen almost a year ago, and the 52-week high of $46.47 was from this past December. The stock now is trading less than 2% lower than at the beginning of the year.

> Shares short: nearly 49.70 million
> Change from prior period: 3.5%
> Percentage of float: 0.7

The number of its shares short has risen for four consecutive periods, but the 52-week high was more than 58 million shares short, posted in January. The average daily trading volume shrank to its lowest level since April, so by the most recent settlement date, the number of days it would take for investors to cover all their short positions had risen to more than two, also a 52-week high.